A new RSV shot could help protect babies this winter—if they can get it in time

A RSV new therapy for infants, called nirsevimab, started shipping in September. By mid-October, demand for nirsevimab, sold under the brand name Beyfortus, had already outstripped supply, according to the pharmaceutical company Sanofi, which developed the drug with AstraZeneca.

In response, the CDC issued interim guidance Oct. 23 to help…